Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome (NCT05521438)

🧪 Interventions in This Study

• QRX003-2% Lotion (DRUG)
• QRX003-4% Lotion QAM (DRUG)
• Vehicle (DRUG)
• QRX003-4% Lotion BID (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (5 Sites)

• Site #1 — San Diego, California
• Site #4 — Indianapolis, Indiana
• Site #5 — Quincy, Massachusetts
• Site #3 — Charleston, South Carolina
• Site #2 — San Antonio, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Netherton Syndrome

• Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome — San Diego, California
• Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome — Chicago, Illinois
• Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome — Fremont, California
• A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 — Palo Alto, California

Explore by condition: All Netherton Syndrome clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.